Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 4;1(2):43-51.
doi: 10.17650/2712-7672-2020-1-2-43-51.

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Aleksandr M Reznik  1   2 , Aleksandr L Arbuzov  1   3 , Sergey P Murin  1
Affiliations
Review

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Aleksandr M Reznik et al. Consort Psychiatr. .

Abstract

Background: Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in Russia. Unlike most other atypical antipsychotics, it shows high in vivo occupancy of dopamine D2 and D3 receptors at clinically relevant doses. In animal models, cariprazine has demonstrated dopamine D3 receptor-dependent pro-cognitive and anti-anhedonic effects, suggesting its potential for treating negative symptoms. This review summarizes the efficacy of cariprazine in the treatment of negative symptoms of schizophrenia.

Methods: A literature search of databases covering international and Russian journals, for articles published between 1st January 2010 and 1st June 2020.

Results: Cariprazine demonstrated at least comparable efficacy in the treatment of schizophrenia symptoms to active comparators including risperidone, olanzapine or aripiprazole. The drug has a good safety profile. It appeared to be associated with a lower risk of metabolic syndromes and most extrapyramidal symptoms. The positive effect of cariprazine on the negative symptoms of schizophrenia may be associated with the elimination of secondary negative symptoms. However, of all the atypical antipsychotics to date, only cariprazine has a convincingly, methodologically robust proven advantage over risperidone in eliminating the predominant negative symptoms of schizophrenia. Yet only four studies have investigated the effect of cariprazine on the negative symptoms of schizophrenia. There is a lack of research into its direct impact on emotional-volitional disorders, anhedonia, cognitive symptoms and personality changes. However, there is evidence to suggest cariprazine is effective in treatment-resistant cases, but this requires further confirmation.

Conclusion: Cariprazine is an effective and well-tolerated agent for the treatment of schizophrenia and may be effective in cases where other antipsychotics have failed. Cariprazine has been shown to have a positive effect on negative symptoms. Further studies are needed to collect more data on long-term treatment of schizophrenia and especially negative symptoms.

Keywords: cariprazine; mental disorders; negative symptoms; schizophrenia; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Kraepelin E. Psychiatrie: Ein Lehrbuch für Studirende und Aerzte. Leipzig: Verlag von J.A. Barth; 1913. https://archive.org/details/psychiatrieeinle02krae/page/n7/mode/2up.
    1. Reynolds J.R. Epilepsy: its symptoms, treatment, and relation to other chronic convulsive diseases. John Churchill; 1861. https://archive.org/details/b21496134/page/n5/mode/2up. - PMC - PubMed
    1. Jackson JH. A dynamic interplay between positive and negative factors in insanity. Levels of dissolution and mental symptoms Dialogues in philosophy, mental and neuro sciences. 2020;13(1):23.:http://www.crossingdialogues.com/Ms-E20-01.htm.
    1. Peralta V, Cuesta M.J. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res. 2001;49(3):269. doi: 10.1016/s0920-9964(00)00071-2. - DOI - PubMed
    1. van Rooijen Geeske, Isvoranu Adela-Maria, Meijer Carin J., van Borkulo Claudia D., Ruhé Henricus G., de Haan Lieuwe. A symptom network structure of the psychosis spectrum Schizophrenia Research. 2017 Nov;189 doi: 10.1016/j.schres.2017.02.018. - DOI - PubMed